Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
...
Health Technology » Pharmaceuticals Major
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| PFE | Pfizer Inc. | 0.18% | 38.52 | 0.9% | $1236.32m | |
| JNJ | Johnson & Johnson | 0.41% | 149.24 | 0.7% | $878.55m | |
| MRK | Merck & Co., Inc. | 0.27% | 81.23 | 0.7% | $636.24m | |
| BMY | Bristol-Myers Squibb Co. | 1.61% | 61.99 | 1.0% | $606.80m | |
| ABBV | AbbVie, Inc. | 0.10% | 93.03 | 1.9% | $598.41m | |
| AZN | AstraZeneca Plc | 0.54% | 55.70 | 1.2% | $567.46m | |
| LLY | Eli Lilly & Co. | 0.06% | 152.97 | 1.1% | $430.35m | |
| NVS | Novartis AG | -0.59% | 82.45 | 0.2% | $139.61m | |
| GSK | GlaxoSmithKline Plc | 0.06% | 40.82 | 0.2% | $136.97m | |
| MIST | Milestone Pharmaceuticals, Inc. | 1.02% | 9.90 | 0.0% | $135.31m | |
| OPK | OPKO Health, Inc. | 0.89% | 5.68 | 11.2% | $133.35m | |
| RGEN | Repligen Corp. | -1.23% | 152.77 | 7.2% | $68.82m | |
| NVO | Novo Nordisk A/S | -0.67% | 64.21 | 0.1% | $68.41m | |
| PRNB | Principia Biopharma, Inc. | 5.33% | 91.89 | 0.0% | $63.33m | |
| SNY | Sanofi | -0.52% | 51.24 | 0.2% | $55.30m |
Company Profile
Royalty Pharma Plc provides drug development services. It operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. The firm's portfolio includes royalties, including AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, and Vertex’s Kalydeco, Symdeko and Trikafta, and four development-stage product candidates. It focuses on acquiring royalty-generating products segment. The firm invests in biopharmaceutical products. The company was founded by Pablo Gerardo Legorreta in 1996 and is headquartered in New York, NY.